Article

Olopatadine 0.2% provides extended efficacy during peak pollen periods

Fort Lauderdale, FL-A new formulation of an anti-allergy medication, olopatadine HCl ophthalmic solution 0.2% (Patanol II, Alcon Laboratories), provides two important advantages. It allows once-daily dosing, which increases patient compliance, and maintains the level of effectiveness of the original formulation, olopatadine 0.1%, during peak pollen seasons for an extended period up to 24 hours, according to Jack Greiner, DO, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.